– Reuters
Profound Medical Announces Preliminary Unaudited Q4 And FY23 Revenues; Sees Q4 Revenue $1.9M-$2M Vs $2.02M Est.; FY23 Revenue $7.1M-$7.2M Vs $7.22M Est.
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue,
